VANCOUVER, BC, March 18, 2015 (GLOBE NEWSWIRE) -- via PRWEB - According to a new report published by iData Research (http://www.idataresearch.com), there has been a significant increase in breast reconstruction procedures in the U.S., driven by women undergoing preventative contralateral prophylactic mastectomies. These surgeries are often based on cancer risk assessments, or aesthetic purposes.
"Even if breast cancer has only been diagnosed in one breast, patients have been moving towards treating and reconstructing both breasts to ensure proper symmetry," explains Dr. Kamran Zamanian, CEO of iData. "This has caused the rate of bilateral reconstructions to skyrocket, and has dramatically impacted the growth of the breast reconstruction market in the United States."
The total market for breast reconstruction in the U.S. is valued at almost USD $500 million. Compared to a much smaller corresponding European market, the difference is clear. The recent increase in U.S. breast reconstruction procedures, primarily due to the rising number of bilateral reconstructions, is contributing to substantial forecasted growth.
As research on the risk factors of breast cancer increases and the development of genetic screenings rise in the U.S., the number of preventative prophylactic double mastectomies will increase over time.
Other key findings from the 2015 edition of the iData Research report entitled U.S. Soft Tissue Reinforcement and Regeneration Market:
Breast Cancer: Generational Differences
The incidence of breast cancer in younger women has been increasing in the United States. Younger patients are more likely to opt for both mastectomy and breast reconstruction. However, elderly patients are less likely to proceed with a mastectomy following a breast cancer diagnosis, and are unlikely to opt for breast reconstruction surgery after the fact.
Leading U.S. Competitors
LifeCell is the leading U.S. competitor in the breast reconstruction market due to their dominance in both the allograft and xenograft segments. Their AlloDerm® allograft product for breast reconstruction, which has amassed favorable clinical evidence supporting its use, sees significant patient satisfaction rates. Since its introduction to the market, AlloDerm® has become the standard for breast reconstruction procedures, despite its premium price.
Other notable competitors in the U.S. breast reconstruction market include C. R. Bard, Covidien, and Ethicon.
For Further Information
More on the markets for breast reconstruction in the U.S. can be found in the 2015 edition report published by iData entitled U.S. Soft Tissue Reinforcement and Regeneration Market, covers the U.S. market segments for hernia repair, dural repair, vaginal slings, skin repair, sports medicine and tendon reinforcement, and dental soft tissue regeneration.
The iData series on the market for soft tissue reinforcement and regeneration devices covers the U.S., and 15 countries in Europe. Full reports also provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players' success strategies in each market and segment.
Register online or email us at info(at)idataresearch(dot)net for a U.S. Soft Tissue Reinforcement and Regeneration Market report brochure and synopsis.
About Procedure Tracker
Procedure number data is available from iData's Procedure Tracker service, which allows subscribers to define and analyze procedure data segmented by State, region, hospital, surgery centre, and physician. A customizable dashboard sorts procedure data for further analysis and research.
About iData Research
iData Research (http://www.idataresearch.com) is an international market research and consulting group focused on providing market intelligence for medical device and pharmaceutical companies. iData covers research in: Diabetes Drugs, Diabetes Devices, Pharmaceuticals, Anesthesiology, Wound Management, Orthopedics, Cardiovascular, Ophthalmics, Endoscopy, Gynecology, Urology and more.
This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2015/03/prweb12591653.htm